Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized study will assess the efficacy and safety of the combination of Pivanex and docetaxel compared to docetaxel alone in patients with a type of lung cancer called non-small cell lung cancer. Pivanex is an investigational agent, and docetaxel is an approved drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Titan Pharmaceuticals
• Treatments: Docetaxel; Histone Deacetylase Inhibitors

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Treatment with one prior platinum-based chemotherapy regimen (Eligible patients may include:

1. Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 months prior to randomization) or

2. Patients who have received chemotherapy for advanced or metastatic lung cancer);

• Recurrent or progressive NSCLC (local, distant, or both) following initial chemotherapy);

• Measurable or non-measurable disease;

• Males and females, age => 18 years;

• Adequate renal function with creatinine => 1.5 mg/dl;

• Adequate liver function with alkaline phosphatase => 2.5 X upper limit of normal, SGOT, and SGPT => 1.5 X upper limit of normal; and total bilirubin => upper limit of normal;

• Adequate bone marrow function: platelets > 100,000/mm3, hemoglobin => 9 g/dL, and absolute neutrophil count (ANC) => 1,500 cells/mm3;

• Able to give informed consent;

• Discontinuation of previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity;

• A predicted life expectancy of at least 12 weeks; and

• ECOG performance status of 0, 1, or 2.

Exclusion Criteria:

• Receipt of more than one chemotherapy regimen for NSCLC;

• A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer;

• Pregnant or lactating females (Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control);

• Known HIV-positive patients;

• Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection;

• Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;

• Patients receiving investigational agents within 30 days of the screening visit;

• Known allergy to reagents in the study;

• Prior docetaxel therapy;

• Symptomatic or untreated brain metastases (Patients with brain metastases are eligible if they are clinically and neurologically stable for > 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife; surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids).